Regression of liver metastases of occult carcinoid tumor with slow release Lanreotide therapy

查看全文 作　　者：Marta [1]Bondanelli;Maria Rosaria [1]Ambrosio;Maria Chiara [1]Zatelli;Luigi [2]Cavazzini;Laura Al Jandali Rifa'[1]y;Ettore C.degli [1]Uberti

机构地区：[1]Department of Biomedical Sciences and Advanced Therapies-Section of Endocrinology;[2]Department of Experimental and Diagnostic Medicine

出　　处：《World Journal of Gastroenterology》索引2005年第11卷第13期,共4页

基　　金：Supported by the Grants From the Italian Ministry of University and Scientific and Technological Research (MIUR 2003069821-001 60%, 2003) 摘　　要：Few clinical studies have demonstrated an anti-proliferative activity of somatostatin (SST) analogs in carcinoids. We report the case of a woman with liver metastases of neuroendocrine tumor and no evidence of the primary tumor. The liver metastases were characterized by high proliferation indes, immunoreactiviy for somatostatin receptor (SSTR) -1,2,3 and 5and positive octreoscan. Urinary 5-hydrozyindolacetic acid, serum serotonin and chromogranin A were elevated. Slow release lanretoide (SR-LAN) therapy for 3 mo controlled clinical and biochemical signs of carcinoid tumor and caused a clear-cut reduction in the diameter of two liver metastases and disappearance of another lesion, with further reduction after 6 and 18 mo. We demonstrated a Clear-cut long-lasting antioccult carcinoid with high proliferation index and immunoreactivity for SSTR-1,2,3, and 5. Immunohistochemistry for SSTRs could be a suitable method for the selection of patients with metasatic carcinoid that may benefit from SST analog therapy. 关键词：肝功能衰竭良性肿瘤生长激素抑制素兰瑞肽药物治疗

相关文献

参考文献（28）
引证文献（7）
耦合文献（0）

参考文献(28)

引证文献(7)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Regression of liver metastases of occult carcinoid tumor with slow release Lanreotide therapy

参考文献(28)

引证文献(7)

用户提示